Skip to main content
Top
Published in: Pituitary 1/2010

01-03-2010

Diagnostic value of 18F-dihydroxyphenylalanine positron emission tomography for growth hormone-producing pituitary adenoma

Authors: Takafumi Taguchi, Toshihiro Takao, Yasumasa Iwasaki, Kenichi Oyama, Shozo Yamada, Mari Inoue, Yoshio Terada

Published in: Pituitary | Issue 1/2010

Login to get access

Excerpt

A 55-year-old woman with signs of acromegaly was referred to our hospital. Endocrinological examinations showed that she had high levels of growth hormone (GH; 5.54 ng ml−1; normal range: 0.66–3.68 ng ml−1) and insulin-like growth factor-I (IGF-I; 508 ng ml−1; normal range: 37–266 ng ml−1) levels, incomplete suppression of serum GH following a 75-gram oral glucose tolerance test (oGTT; trough GH 3.66 ng ml−1), and paradoxical GH responses to a TRH provocation test (peak GH 38.9 ng ml−1). Dynamic magnetic resonance imaging (MRI) suggested the presence of an intrasellar mass lesion (5.9 × 2.8 mm) in the left part of her pituitary gland (Fig. 1a, upper panel). F-18 fluorodeoxyglucose (FDG) positron emission tomographic (PET) imaging clearly showed focal but remarkable FDG uptake (Fig. 1a, lower panel), consistent with the localization of the tumor suspected on MRI. The tumor was removed by transsphenoidal surgery. Subsequent histological analysis confirmed the diagnosis of a GH-producing pituitary adenoma. After removal, serum IGF-I levels decreased to a normal range (178 ng ml−1), and serum GH was appropriately suppressed during oGTT (trough GH 0.30 ng ml−1), suggesting that complete resection was obtained [1]. While postsurgical changes made it difficult to detect any residual lesion on MRI (Fig. 1b, upper panel), abnormal FDG uptake was not seen on FDG-PET after surgery (Fig. 1b, lower panel).
Literature
1.
go back to reference Carmichael JD, Bonert VS, Mirocha JM, Melmed S (2009) The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly. J Clin Endocrinol Metab 94:523–527. doi:10.1210/jc.2008-1371 CrossRefPubMed Carmichael JD, Bonert VS, Mirocha JM, Melmed S (2009) The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly. J Clin Endocrinol Metab 94:523–527. doi:10.​1210/​jc.​2008-1371 CrossRefPubMed
2.
3.
go back to reference De Souza B, Brunetti A, Fulham MJ, Brooks RA, DeMichele D, Cook P et al (1990) Pituitary microadenomas: a PET study. Radiology 177:39–44PubMed De Souza B, Brunetti A, Fulham MJ, Brooks RA, DeMichele D, Cook P et al (1990) Pituitary microadenomas: a PET study. Radiology 177:39–44PubMed
Metadata
Title
Diagnostic value of 18F-dihydroxyphenylalanine positron emission tomography for growth hormone-producing pituitary adenoma
Authors
Takafumi Taguchi
Toshihiro Takao
Yasumasa Iwasaki
Kenichi Oyama
Shozo Yamada
Mari Inoue
Yoshio Terada
Publication date
01-03-2010
Publisher
Springer US
Published in
Pituitary / Issue 1/2010
Print ISSN: 1386-341X
Electronic ISSN: 1573-7403
DOI
https://doi.org/10.1007/s11102-009-0208-9

Other articles of this Issue 1/2010

Pituitary 1/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine